How I Diagnose Minimal/Measurable Residual Disease in B Lymphoblastic Leukemia/Lymphoma by Flow Cytometry

Reduced-dose-intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study

(2020) Francisco Pedrosa et al.   BLOOD

A systematic review of outcomes after stem cell transplantation in acute lymphoblastic leukemia with or without measurable residual disease

(2020) Shweta Shah et al.   LEUKEMIA & LYMPHOMA

Evaluation and management of measurable residual disease in acute lymphoblastic leukemia

(2020) Iman Abou Dalle et al.   Therapeutic Advances in Hematology

Flow cytometric predictive scoring systems for common fusions ETV6/RUNX1, BCR/ABL1, TCF3/PBX1 and rearrangements of the KMT2A gene, proposed for the initial cytogenetic approach in cases of B-acute lymphoblastic leukemia

(2019) Nikolaos J. Tsagarakis et al.   International Journal of Laboratory Hematology

Applications of Flow Cytometric Immunophenotyping in the Diagnosis and Posttreatment Monitoring of B and T Lymphoblastic Leukemia/Lymphoma

(2019) Joseph A. DiGiuseppe et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Comparison of minimal residual disease levels in bone marrow and peripheral blood in adult acute lymphoblastic leukemia

(2019) Michaela Kotrova et al.   LEUKEMIA

Role of CD81 and CD58 in minimal residual disease detection in pediatric B lymphoblastic leukemia

(2018) E. Tsitsikov et al.   International Journal of Laboratory Hematology

Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children’s Oncology Group (COG)

(2018) Sumit Gupta et al.   LEUKEMIA

No prognostic significance of immunophenotypic changes at the end of remission induction therapy in children with B-lineage acute lymphoblastic leukemia

(2018) Qingkai Dai et al.   LEUKEMIA RESEARCH

Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts

(2018) Nicholas J. Short et al.   AMERICAN JOURNAL OF HEMATOLOGY

FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia

(2018) Maura C. O’Leary et al.   CLINICAL CANCER RESEARCH

FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease

(2018) Emily Y. Jen et al.   CLINICAL CANCER RESEARCH

Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia

(2017) Donald A. Berry et al.   JAMA Oncology

Excellent outcome of minimal residual disease-defined low-risk patients is sustained with more than 10 years follow-up: results of UK paediatric acute lymphoblastic leukaemia trials 1997–2003

(2016) Jack Bartram et al.   ARCHIVES OF DISEASE IN CHILDHOOD

Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia

(2016) Prisca Theunissen et al.   BLOOD

Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy

(2016) R. Gardner et al.   BLOOD

A novel flow cytometric assay for detection of residual disease in patients with B-lymphoblastic leukemia/lymphoma post anti-CD19 therapy

(2016) Sindhu Cherian et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000-000

(2016) Prashant R. Tembhare et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group

(2016) Rob Pieters et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy

(2016) C-H Pui et al.   LEUKEMIA

Lineage Switch in MLL-Rearranged Infant Leukemia Following CD19-Directed Therapy

(2016) Ahmad Rayes et al.   PEDIATRIC BLOOD & CANCER

Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies

(2016) Marco Ruella et al.   Computational and Structural Biotechnology Journal

B-ALL Minimal Residual Disease Flow Cytometry

(2015) Aaron C. Shaver et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232

(2015) M. J. Borowitz et al.   BLOOD

Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies

(2015) J. J. M. van Dongen et al.   BLOOD

Characterization of CD22 expression in acute lymphoblastic leukemia

(2015) Nirali N. Shah et al.   PEDIATRIC BLOOD & CANCER

Differential Expression of CD200 in B-Cell Neoplasms by Flow Cytometry Can Assist in Diagnosis, Subclassification, and Bone Marrow Staging

(2014) Pramoda Challagundla et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Detection of Minimal Residual Disease in B Lymphoblastic Leukemia by High-Throughput Sequencing of IGH

(2014) D. Wu et al.   CLINICAL CANCER RESEARCH

Apparent CD19 expression by natural killer cells: A potential confounder for minimal residual disease detection by flow cytometry in B lymphoblastic leukemia

(2014) Lorinda Soma et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Detection and management of minimal residual disease in acute lymphoblastic leukemia

(2014) M. Schrappe   Hematology-American Society of Hematology Education Program

Detection of minimal residual disease in pediatric acute lymphoblastic leukemia

(2013) Giuseppe Gaipa et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Validation of cell-based fluorescence assays: Practice guidelines from the ICSH and ICCS - part V - assay performance criteria

(2013) Brent Wood et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Technical issues: flow cytometry and rare event analysis

(2013) B. D. Hedley et al.   International Journal of Laboratory Hematology

Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial

(2013) Ajay Vora et al.   LANCET ONCOLOGY

Lineage switch in childhood acute leukemia: An unusual event with poor outcome

(2012) Jorge G. Rossi et al.   AMERICAN JOURNAL OF HEMATOLOGY

New markers for minimal residual disease detection in acute lymphoblastic leukemia

(2011) E. Coustan-Smith et al.   BLOOD

Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: Results of Children's Oncology Group trial P9906

(2011) W. Paul Bowman et al.   PEDIATRIC BLOOD & CANCER

Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study

(2010) V. Conter et al.   BLOOD

Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia

(2010) P. Stow et al.   BLOOD

CD66c expression in B-cell acute lymphoblastic leukemia: strength and weakness

(2010) N. GUILLAUME et al.   International Journal of Laboratory Hematology

Characterization of Immunophenotypic Aberrancies in 200 Cases of B Acute Lymphoblastic Leukemia

(2009) Adam C. Seegmiller et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Distinct Expression Patterns of CD123 and CD34 on Normal Bone Marrow B-Cell Precursors (“Hematogones”) and B Lymphoblastic Leukemia Blasts

(2009) Nagwa M. Hassanein et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study

(2008) M. J. Borowitz et al.   BLOOD

Hematogones in acute leukemia during and after therapy

(2008) Ol'ga Babušíková et al.   LEUKEMIA & LYMPHOMA